Stocks rose sharply on Monday as Treasury yields rebounded, quelling fears of a possible recessionUS Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Amid the headlines of stores closures and retail bankruptcies, it can be tough to accept that the U.S. consumer is doing just fine.Retailread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
HelloFresh will start carrying Beyond Meat's vegan burger on its U.S. menus in September.Restaurantsread more
Goldman notes that high-dividend payers are trading at their largest valuation discount in nearly 40 years.Marketsread more
CNBC Make It set out to find the schools that provide middle-class American students the highest average salaries for their tuition dollars. Stanford is No. 1 on CNBC Make...Definitive Guide to Collegeread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
The U.S. Food and Drug Administration just released its guidance on a category of software called "clinical decision support," which is designed to help doctors make more data-driven decisions about patient care.
It sounds wonky, but companies for years have been begging for clarity on whether this type of software is regulated -- or it isn't.
Experts say that lack of clarity is holding back start-ups and big companies alike in their attempt to bring new technologies to health. That includes Apple's plans to use its smartwatch to detect irregularities with the heart's rhythm and notify users if they need a medical consultation.
"I know developers who sat in my office and told me they didn't build a life-saving feature because they didn't know if it would be regulated or not," said Morgan Reed, president of an app developers' interest group called ACT.
Three documents from the FDA remove some doubts by describing various types of medical software and what sorts of claims would be regulated.
Reed said it's now clear that if a doctor makes the decision and diagnosis, and uses software to make more informed decisions about treatment, that software would not be regulated.
It would be regulated, however, if the software makes a diagnosis. For instance, if it notifies a user that they have a specific medical condition.
Reed said this category of software is so important as it takes some of the guesswork out of medicine.
Previously, doctors made decisions based on patients they've seen with a similar condition and background. "If you're lucky, that's 500 people who look like you," said Reed. But with new technology from "thousands of doctors on millions of patients," he said, treatments will be more evidence-based.
Apple, Google, Fitbit and others are all working with FDA as it figures out how to fast-track the approval process for digital health companies.
Some people in the industry think the guidance does not go far enough.
Some clinical decision support software is more "risky" to a patient than others. For instance, some app makers will recommend chemotherapy to a cancer patient based on information in their database. Others will merely use data to predict a risk score for populations of people who are more likely to develop migraines.
Bradley Merrill Thompson, an FDA expert and lawyer with the firm Epstein, Becker & Green, would have liked to see FDA distinguish between these various use-cases based on risk.
"We didn't get that," he wrote in an email. "Worse, it appears based on the guidance that the FDA is not interested in drawing that line."